CHMP brushes off Radius osteoporosis treatment

EMA's CHMP recommended against approval of Radius' Eladynos abaloparatide-SC to treat osteoporosis in postmenopausal women at increased risk for fracture. Radius said it plans to request a re-examination.

Abaloparatide-SC is a subcutaneous peptide analog of parathyroid hormone-related protein (PTHrP) marketed as Tymlos for the indication in the U.S. (see BioCentury, May 4, 2017)...